Clinical Trial Update: Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis [Phase 2]

View source ↗

Summary

A Phase 2 study to evaluate the efficacy and safety of K-877-ER and CSG452 in participants with nonalcoholic steatohepatitis (NASH) with liver fibrosis. The tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Steatohepatitis

Drugs mentioned

• CSG452
• K-877-ER (pemafibrate)

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: NASH | Phase 2 | Status: ACTIVE_NOT_RECRUITING